OptimizeRx Corp. (NASDAQ:OPRX) Shares Bought by Blair William & Co. IL

Key Points

• Blair William & Co. IL increased its stake in OptimizeRx Corp. by 4.9% in the first quarter, owning approximately 3.41% of the company, valued at $5,465,000.
• OptimizeRx reported earnings of $0.08 per share, exceeding analysts' expectations of ($0.11), along with revenues of $21.93 million for the quarter.
• Wall Street analysts have generally given OptimizeRx a favorable outlook, with nine analysts rating it as a "buy" and an average target price of $10.81.

Blair William & Co. IL grew its stake in shares of OptimizeRx Corp. (NASDAQ:OPRX - Free Report) by 4.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 631,031 shares of the company's stock after acquiring an additional 29,648 shares during the period. Blair William & Co. IL owned about 3.41% of OptimizeRx worth $5,465,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of OPRX. Whetstone Capital Advisors LLC acquired a new position in OptimizeRx during the fourth quarter worth $6,563,000. Kennedy Capital Management LLC raised its stake in shares of OptimizeRx by 57.8% during the 4th quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company's stock worth $2,887,000 after buying an additional 217,676 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of OptimizeRx by 9.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 444,167 shares of the company's stock worth $2,159,000 after buying an additional 39,740 shares in the last quarter. Geode Capital Management LLC grew its stake in OptimizeRx by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 400,621 shares of the company's stock valued at $1,948,000 after acquiring an additional 4,821 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. increased its holdings in OptimizeRx by 12.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 295,717 shares of the company's stock valued at $1,437,000 after acquiring an additional 32,062 shares in the last quarter. Hedge funds and other institutional investors own 76.47% of the company's stock.

OptimizeRx Trading Down 0.4%

NASDAQ:OPRX opened at $12.48 on Thursday. OptimizeRx Corp. has a one year low of $3.78 and a one year high of $15.71. The business's 50-day simple moving average is $13.39 and its 200 day simple moving average is $9.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.82 and a current ratio of 2.82. The stock has a market cap of $230.82 million, a price-to-earnings ratio of -14.86, a price-to-earnings-growth ratio of 4.18 and a beta of 1.33.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.19. OptimizeRx had a negative net margin of 16.33% and a negative return on equity of 0.29%. The firm had revenue of $21.93 million for the quarter, compared to analysts' expectations of $18.69 million. As a group, sell-side analysts predict that OptimizeRx Corp. will post -0.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

OPRX has been the topic of several research reports. Wall Street Zen upgraded shares of OptimizeRx from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. B. Riley reiterated a "buy" rating on shares of OptimizeRx in a report on Tuesday, May 13th. JMP Securities upped their price objective on OptimizeRx from $11.00 to $14.00 and gave the company a "market outperform" rating in a research report on Tuesday, May 13th. Citigroup reiterated an "outperform" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Finally, Roth Capital reaffirmed a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $10.81.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

Want to see what other hedge funds are holding OPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptimizeRx Corp. (NASDAQ:OPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.